Biopharma financings from January through September 2025 totaled $47.1 billion, a sharp decline from 2024’s $86.7 billion during the same period and well below the highs of 2020 and 2021. The slowdown ...

Nanyang Biologics Pte. Ltd. has entered a $1.5 billion business combination agreement with RF Acquisition Corp II, a ...

The U.S. FDA device center’s guidance agenda for fiscal 2026 is the classic case of something old and something new, but what ...

Bacterial resistance remains one of the biggest obstacles to antibiotic efficacy and spurs the constant search for ...

The U.S. FDA has approved the priority sNDA for a new first-line maintenance therapy in extensive-stage small-cell lung ...

Like a scene from a movie, a British beauty influencer and a German disabled war veteran could provide just the spark that ...

Genetic mutations are the primary cause of most rare diseases. Although each condition affects a small fraction of the ...

Although type 2 diabetes tends to get more airtime, type 1 diabetes also had drawn a number of the developers to the table. Recently winning the attention of Wall Street is SAB Biotherapeutics Inc., ...

Sovargen Co. Ltd. inked a $550 million license deal with Angelini Pharma SpA, granting Angelini development and commercialization rights to SVG-105, a novel antisense oligonucleotide drug candidate in ...

Vitiligo is caused by autoreactive CD8+ T cells that react against skin melanocytes, where IL-15 has been shown to activate these T cells. Innovent Biologics (Suzhou) Co. Ltd. recently presented data ...

Idiopathic pulmonary fibrosis (IPF) is a rapidly progressing lung disease with high unmet needs and characterized by an excess in matrix deposition that leads to severe decline in lung functioning, ...

Dem Biopharma Inc. has divulged G-protein coupled receptor 84 (GPR84) agonists and phagocytosis inducers reported to be useful for the treatment of cancer, infections, neurological disorders and ...